Bartlett

Researchers are conducting a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to evaluate the effects of teplizumab compared with placebo in children and young adults aged 1 to 25 years with recently diagnosed Stage 3 type 1 diabetes. The study aims to measure changes in blood sugar control and independence from mealtime insulin over 52 weeks while participants continue standard insulin therapy. Participants will be randomly assigned to receive either increasing doses of teplizumab or a matching placebo, both given by intravenous IV infusion. The treatment period lasts 52 weeks, during which participants receive the study drug or placebo by IV infusion. The total study duration for each participant is approximately 84 weeks 19 months, including treatment and follow-up. Throughout the study, participants will undergo regular assessments including blood tests measuring glycated hemoglobin HbA1c, C-peptide levels from meal tolerance tests, and continuous glucose monitoring to track blood sugar levels. Researchers will also monitor insulin use, adverse events, drug concentrations in the blood, and antibody responses. Safety and efficacy are evaluated up to 78 weeks, with multiple visits scheduled across the study period.

Researchers are comparing the rates of surgical and minimally invasive interventions, as well as any harms, in Medicare beneficiaries treated with the MILD procedure versus those treated with interspinous process decompression IPD for lumbar spinal stenosis with neurogenic claudication. This observational study uses Medicare claims data to follow patients for 24 months after their initial procedure starting from January 1, 2017. The purpose is to evaluate outcomes between these two types of procedures without requiring prior patient enrollment or consent. The study includes two groups patients who received MILD, which is a percutaneous image-guided lumbar decompression performed under fluoroscopic guidance through a dorsal approach to the spine, and patients who received IPD, a different device-based decompression procedure. Data on reoperations and complications will be collected for both groups over a 24-month follow-up period using Medicare claims. Enrollment continues until the sponsor decides to stop. Participants involvement is passive as the study uses existing Medicare claims data. Researchers will monitor rates of harms related to the initial procedure and subsequent surgical or minimally invasive interventions over two years. No direct patient visits or interventions are conducted, and the study is exempt from institutional review board oversight. The total study duration extends to December 2026, covering cases treated since early 2017.

Researchers are evaluating the effectiveness and safety of palazestrant combined with ribociclib compared to letrozole combined with ribociclib in adults with advanced breast cancer that is estrogen receptor positive ER and human epidermal growth factor receptor 2 negative HER2-. This phase 3 clinical trial includes women and men who have not yet received systemic treatment for their advanced breast cancer, aiming to find improved first-line treatment options. Participants are randomly assigned to one of two groups one group receives palazestrant 90 mg daily with ribociclib 600 mg daily taken on days 1-21 of each 28-day cycle plus a placebo matching letrozole the other group receives letrozole 2.5 mg daily with ribociclib 600 mg daily plus a placebo matching palazestrant. Treatments are given in repeating 28-day cycles. The study is double-blind and active-controlled, meaning neither participants nor researchers know who receives which treatment, and both groups receive active drugs. During the trial, participants will be monitored regularly for disease progression and survival over approximately 3.5 to 5.5 years. Assessments include tumor response evaluations, safety and tolerability checks, pharmacokinetic blood tests every 28 days, and patient-reported health outcomes. The primary outcome is progression-free survival, measuring the time from randomization until disease worsens or death. Safety monitoring continues for up to 42 days after treatment ends, with the study lasting until 2032.

This research focuses on Stage 2 Type 1 Diabetes T1D, an early phase marked by abnormal blood sugar levels without clear symptoms. The study aims to gather information about patients with Stage 2 T1D and to observe the long-term effects of TZIELD teplizumab-mzwv, a drug approved by the U.S. FDA to delay the progression to clinical T1D in adults and children aged 8 years and older. This is an observational study where no treatments are administered by the researchers. Instead, patients who are either about to start or have recently started TZIELD treatment within six months, as well as patients not receiving TZIELD, will be followed. The study records the use of TZIELD as prescribed in real-world clinical practice without interference. Participants will be monitored for up to about 10 years to track adverse events, serious adverse events, maternal and infant outcomes if exposed during pregnancy, and infant development up to 12 months after birth. Data will be collected through routine clinical assessments and safety monitoring, helping to understand the long-term safety of TZIELD in this patient group.

Researchers are evaluating a treatment for participants with untreated, unresectable, or metastatic melanoma at advanced stages Stage IIIC, IIID, or IV. This Phase 3, multicenter, open-label study compares a combination of lifileucel and pembrolizumab against pembrolizumab alone, focusing on efficacy and safety. The study includes participants who have not received prior therapy for metastatic disease, though some prior adjuvant or neoadjuvant therapies completed at least 6 months before progression are allowed. Participants in the study are assigned to one of two groups one receives pembrolizumab with lifileucel, and the other receives pembrolizumab alone. Lifileucel treatment involves surgically removing a tumor sample for manufacturing, followed by lymphodepletion, lifileucel infusion, and IL-2 therapy. Pembrolizumab is administered every 6 weeks until disease progression. Participants initially receiving pembrolizumab alone who experience confirmed disease progression may opt to receive lifileucel monotherapy in an optional crossover period. During the study, participants undergo tumor resection and regular treatment cycles. Researchers will assess outcomes such as objective response rate, progression-free survival, overall survival, complete response rate, duration of response, event-free survival, and adverse events over several years. Safety and efficacy are monitored throughout, with follow-up lasting up to 7 years to evaluate long-term outcomes and disease progression.